ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science ...

NAD infusions are just one of the latest crazes for longevity-seekers, but can it really help you live longer? Here’s what an ...

The authors have demonstrated the use of adenine base editors delivered via adeno-associated viruses to introduce edits in the mitochondrial genome. The manuscript describes the methodology well, and ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

Blood transfusion is one of the cornerstones of modern medicine, used in a spectrum of situations from traumatic injuries to chronic illnesses that impair red blood cell production. About every two ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...

Tools for advanced health treatments can help you fine tune your fitness and health goals. Try out DEXA scans, red light ...

StockNews.com lowered shares of ChromaDex (NASDAQ:CDXC – Free Report) from a strong-buy rating to a buy rating in a research ...

Discover 7 ways to reverse aging with specific diet and exercise tips that transform energy levels, slow cellular decline, ...

ChromaDex Corporation’s CDXC share price has dipped by 10.06%, which has investors questioning if this is right time to buy.

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.